Apellis Pharmaceuticals Inc

APLS

NASDAQ. Currency in USD

49.01 -1.68 ( -3.21% )

Real time prices: December 05

Market Cap.
5.42B
Beta (5Y monthly)
1.24
Price/Earnings
-
EPS (TTM)
-6.24
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
889,832
1y Target Est.
74.24
Day's Range
49.26
-
51.70
52 Week's Range
33.32
-
70.00

Historical Summary

Performance
EPS growth
Share Buybacks

About Apellis Pharmaceuticals Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.apellis.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
97.36M
Employees
476
Address
100 Fifth Avenue, Waltham, MA, United States, 02451
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.

Latest news

Biotech Stock Roundup: CTMX Surges on REGN's Deal, APLS Up on Regulatory Update
Biotech Stock Roundup: CTMX Surges on REGN's Deal, APLS Up on Regulatory Update

Updates from CTMX and APLS are the key highlights from the biotech sector during the...
By Zacks Investment Research - 1 week ago

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) --  Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global...
By GlobeNewswire Inc. - 1 week ago

Apellis (APLS) Rises on FDA Acceptance of NDA Amendment for GA
Apellis (APLS) Rises on FDA Acceptance of NDA Amendment for GA

The FDA accepts Apellis' (APLS) major amendment to the NDA for pegcetacoplan to treat geographic...
By Zacks Investment Research - 2 weeks ago

Why InMed Pharmaceuticals Shares Tumbled 28%; Here Are 67 Biggest Movers From Friday
Why InMed Pharmaceuticals Shares Tumbled 28%; Here Are 67 Biggest Movers From Friday

Gainers AGBA Group Holding Limited (NASDAQ: AGBA) gained 50.7% to close at $6.78 on Friday....
By Benzinga - 2 weeks ago

Foot Locker, Ross Stores, Palo Alto Networks, And Other Big Gainers From Friday
Foot Locker, Ross Stores, Palo Alto Networks, And Other Big Gainers From Friday

U.S. stocks closed higher on Friday, with the Dow Jones gaining around 200 points. Here...
By Benzinga - 2 weeks ago

Why PaxMedica Shares Are Trading Higher By Over 53%? Here Are 47 Stocks Moving In Friday's Mid-Day Session
Why PaxMedica Shares Are Trading Higher By Over 53%? Here Are 47 Stocks Moving In Friday's Mid-Day Session

Gainers PaxMedica, Inc. (NASDAQ: PXMD) gained 53.5% to $2.38 after the company announced an equity...
By Benzinga - 2 weeks ago

Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)
Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)

WALTHAM, Mass., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global...
By GlobeNewswire Inc. - 2 weeks ago

Benzinga's Top Ratings Upgrades, Downgrades For November 10, 2022
Benzinga's Top Ratings Upgrades, Downgrades For November 10, 2022

Upgrades According to Stifel, the prior rating for Clearside Biomedical Inc (NASDAQ:CLSD) was changed from...
By Benzinga - 3 weeks ago